Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
26 papers
Research points to two clear groups of treatments for anxiety. First, ordinary approaches like exercise — especially walking and other regular physical activity — have strong, high-quality evidence showing medium-sized reductions in anxiety symptoms. These are proven in many randomized trials and reviews. Second, newer substance-assisted therapies (often called psychedelic‑assisted therapy) are promising. Small clinical trials and reviews show reductions in anxiety and related problems after carefully supervised doses of drugs such as psilocybin, MDMA, ketamine, and ayahuasca. However, these drug approaches are mostly early-stage or done in special research settings and need more, larger trials before they can become routine care. People thinking about or treating anxiety should know that drug‑assisted therapies are almost always given together with serious psychological support. How the drug is given, the preparation before it, and follow-up therapy matter a lot. There are also safety and equity issues to watch: some psychedelics can have rare lasting side effects, many studies are small, and people of color have been underrepresented in trials. For now, exercise has the clearest and broadest evidence. Other treatments are promising but still need more testing and careful medical oversight.
This randomized, double‑blind, cross‑over trial gave 51 patients with life‑threatening cancer two sessions of psilocybin (one very low dose and one high dose) spaced five weeks apart. The high dose (22–30 mg/70 kg) produced large drops in clinician‑ and self‑rated depression and anxiety, and increased quality of life, meaning, and…
This paper pooled data from six randomized, double‑blind phase‑2 trials of MDMA‑assisted psychotherapy for adults with PTSD (total N=103). After two blinded MDMA sessions, the MDMA group showed larger reductions in clinician‑rated PTSD symptoms than the control group (mean difference −22.0 points on the CAPS‑IV, P < 0.001) and a…
This 2019 systematic review looked at human studies of medicinal cannabis and cannabis-derived isolates for major psychiatric disorders. The authors found that the evidence is very new and limited, so it is too early to recommend cannabis medicines for psychiatric conditions. Some small or isolated studies suggest benefits for a…
This review explains why the FDA gave Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD. It summarizes six Phase 2 trials (2004–2017) in which MDMA was given in up to three 8-hour sessions combined with preparatory and follow-up therapy, and pooled analyses showed a large effect on PTSD symptoms and…
This small, randomized, double-blind pilot study tested MDMA-assisted psychotherapy for anxiety tied to life‑threatening illness. Eighteen people were enrolled (13 got MDMA, 5 got placebo) and had two blinded 8‑hour therapy sessions, with later open‑label MDMA sessions and 6‑ and 12‑month follow-ups. The MDMA group showed a larger drop in…
This systematic review looked at human studies of cannabidiol (CBD) for anxiety up to June 2019. Eight studies were included (6 small randomized controlled trials, 1 case series, and 1 case report). The studies tested CBD for anxiety in healthy volunteers, generalized anxiety disorder, social anxiety disorder, and PTSD-related anxiety.…
This review looked at animal and human studies of cannabidiol (CBD) for anxiety. In animals, CBD often reduced anxiety-like behaviors at low or medium doses but sometimes increased anxiety at high doses. Small human studies and public-speaking tests suggest CBD might reduce anxiety in healthy people and in social anxiety…
Project Twenty21 is the UK’s first medical cannabis registry. It began in August 2020 to collect real-world data because randomized trials are hard and NHS prescribing remained rare after medical cannabis was legalised in November 2018. By 12 March 2021, 678 people had joined; most were men and the most…
This review looked at human studies up to July 2020 about THC (the main psychoactive part of Cannabis) and its effects on fear-related memories and anxiety. The authors report that low doses of THC can speed up extinction of aversive memories and lower anxiety in people, and that combining THC…
Researchers looked at sixty studies to see how biology, social life, and psychology mix together to affect substance use problems and mental health. They found that brain systems, genes, childhood experiences, parenting, personality, and existing mood or anxiety problems all interact. This makes addiction and related psychiatric symptoms complicated, especially…
This review looks at research on cannabis compounds and the body’s endocannabinoid system as possible treatments for depression, bipolar disorder, anxiety, PTSD, and schizophrenia. It says the evidence is mixed and mostly preliminary. Some studies show biological links between the endocannabinoid system and mood disorders, and early clinical work suggests…
